Transforming Pathology with AI: PaigeAI's Breakthrough in Cancer Care #healthtechinnovation

Pathology is the study of cells under a microscope, it is a critical field in healthcare, particularly in cancer diagnosis. However, a significant challenge in pathology is the inconsistency in reports and occasional disagreement between pathologists. This can lead to variations in cancer diagnosis and treatment, impacting patient care. To address these critical issues, One such groundbreaking approach is the integration of Artificial Intelligence (AI) in pathology, which is Pioneered by companies like PaigeAI.

PaigeAI, is a company in the field of digital diagnostics, they are using next-generation computational technology, machine learning, and artificial intelligence to revolutionize cancer diagnosis. PaigeAI's platform and AI applications, including the Paige Prostate Suite and Paige Breast Suite, have been instrumental in streamlining pathology workflows. They provide actionable diagnostic insights that directly affect patient care.

With their solutions they have shown a remarkable 70% reduction in cancer detection errors and a substantial decrease in the time taken for diagnosis.

As the first company to receive FDA approval for an AI application in pathology, PaigeAI has set a new standard in the field.

Join me today as we talk to Dr. Moye the CEO of PaigeAI

Time stamps:
1:33 AI in Cancer Care: Revolutionizing Diagnosis
4:25 Improving Cancer Diagnostics with AI and Machine Learning
10:45 The Role of AI in Predicting Biomarkers and Treatment Responses
24:28 Navigating Healthcare Economics: The Path to AI Integration
34:01 Measures does Paige.AI take to ensure the accuracy of its results
38:44 Every test has its limitations
40:33 Personal Journey: From Science to AI-Driven Healthcare Entrepreneurship
43:41 Challenges of integrating AI in pathology
47:20 Building Teams for Healthcare Innovation: Bridging Technology and Medicine

Roupen Odabashian:

Andy Moye, PhD

Paige.AI